NCT05179486Recruiting
Molecular Epidemiology of Biliary Tree Cancers
Source: ClinicalTrials.gov · Last updated 17 Apr 2026
Brief summary (registry, in English)
This study is to learn if certain risk factors (environmental, viral, behavioral, medical, and dietary), tumor markers, and genetic changes can predict the development and outcome of biliary tree cancers. Establishing biomarkers models from patients may help doctors to further understand how biliary tree cancer is affected by different treatments, and why some people's cancer responds differently than others.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1500 (estimated)
- First submitted
- 13 Dec 2021
- Start date
- 25 Sept 2017
- Primary completion date
- 2 Feb 2027
- Lead sponsor
- M.D. Anderson Cancer Center
- NCT number
- NCT05179486
What you commit to
- Study type: Observational
- Planned participants: 1500
- From 25 Sept 2017 to the primary completion date, 2 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Pathologically or radiologically confirmed diagnosis of CGC or GBC
- With or without prior radiation or chemotherapy
- All United States of America (USA) and non USA residents
- No age, gender, or racial restriction
- Healthy control with no current or history of cancer
- Healthy controls are USA and non USA residents
- Healthy controls are matched to the cases in age (5 years), gender, and race
- Healthy controls are friends and spouses of patients with other than gastro-intestinal (GI) cancers
- Chronic Liver Disease (CLD) controls with no current or history of cancer
- CLD controls are USA and non USA residents
- CLD controls are frequency matched to CGC cases by age (5 years), gender, and race
- CLD controls are patients are diagnosed with or without liver biopsy (core or fine needle aspiration)
- CLD controls must not have evidence liver cancer diagnosis by computed tomography (CT) or magnetic resonance imaging (MRI)
Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.